Bris­tol My­er­s' Op­di­vo turns the boat around in Q2 as man­u­fac­tur­ing is­sues haunt CAR-T launch

What a dif­fer­ence a quar­ter can make.

Sting­ing from a dip in sales for I/O block­buster Op­di­vo last quar­ter, Bris­tol My­ers Squibb’s top check­point in­hibitor turned the boat around in Q2, post­ing 16% growth from the same time­frame in 2020 to $1.91 bil­lion.

On a call with an­a­lysts, Bris­tol My­ers ex­ecs cit­ed the turn­around to Op­di­vo’s on­go­ing gas­tric can­cer launch as well as the in­evitable turn­around in pre­scrib­ing as the Covid-19 pan­dem­ic be­gins to wane. It’s a strong show­ing for Op­di­vo de­spite the fact that the Op­di­vo com­bo with CT­LA4 in­hibitor Yer­voy con­tin­ues turn­ing up red flags.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER